Why is Strides Pharma falling/rising?

Recent Price Movement and Market Context

Strides Pharma’s stock has experienced a modest pullback over the past week, declining by 2.06%, in contrast to the Sensex which gained 0.56% during the same period. The stock has underperformed its sector by 2.03% on the day, continuing a two-day losing streak that has resulted in a cumulative fall of 3.06%. This short-term weakness is reflected in the stock trading below its 5-day and 20-day moving averages, although it remains comfortably above its 50-day, 100-day, and 200-day averages, signalling that the longer-term trend remains intact.

Investor participation has also waned recently, with delivery volumes on 27 Nov dropping sharply by 68.69% compared to the five-day average. This decline in trading activity suggests a cautious stance among investors, possibly awaiting clearer signals before committing further capital.

Strong Fundamentals Support Long-Term Outlook

Despite the recent price softness, Strides Pharma continues to demonstrate solid operational performance. The company has reported positive results for nine consecutive quarters, with key profitability metrics reaching record highs. Its operating profit to interest ratio stands at an impressive 5.02 times, while quarterly PBDIT and PBT less other income have peaked at ₹231.56 crores and ₹134.75 crores respectively. These figures underscore the company’s efficient cost management and strong earnings quality.

Moreover, Strides Pharma boasts a return on capital employed (ROCE) of 15.6%, reflecting effective utilisation of capital to generate profits. The stock’s enterprise value to capital employed ratio of 2.2 indicates an attractive valuation, trading at a discount relative to its peers’ historical averages. This valuation appeal is further supported by the stock’s impressive long-term returns, having delivered 439.30% over three years and 138.66% over five years, significantly outperforming the Sensex and broader market indices.

However, it is important to note that while the stock has generated a 14.44% return over the past year, the company’s profits have declined by 14.7% during the same period. This divergence between price appreciation and earnings contraction may be contributing to the recent cautious sentiment among investors.

Consistent Outperformance Amid Market Volatility

Strides Pharma has consistently outperformed the BSE500 index over the last three annual periods, reinforcing its status as a resilient stock within the pharmaceuticals sector. Its year-to-date return of 33.23% far exceeds the Sensex’s 9.68%, highlighting strong investor confidence in its growth prospects despite short-term fluctuations.

Conclusion: Short-Term Correction Amid Strong Fundamentals

The recent decline in Strides Pharma’s share price on 28-Nov appears to be a short-term correction driven by reduced investor participation and profit-taking after a strong run-up. While the stock has underperformed the sector and broader indices in the immediate term, its long-term performance remains robust, supported by consistent profitability, attractive valuation, and solid returns relative to benchmarks.

Investors should weigh the current dip against the company’s strong operational metrics and historical outperformance. The stock’s discount to peer valuations and healthy return on capital employed suggest that the recent price weakness may present a buying opportunity for those with a longer investment horizon.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →